Genetic Technologies share consolidation update

Genetic Technologies Limited (ASX:GTG) has announced a further change to the timetable for the implementation of the shareholder approved 100:1 share consolidation. This adjustment aims to ensure that the Company's securities trade on both the ASX and NASDAQ, on the same consolidated basis, from the same date.

Executive commentary on share consolidation update

The Company wishes to advise shareholders about the updated timetable for the implementation of the 100:1 share consolidation. This change is necessary to ensure that the Company's securities trade on both the ASX and NASDAQ, on the same consolidated basis, from the same date.

Summary of Genetic Technologies share consolidation update

Genetic Technologies Limited (ASX:GTG) has made a further change to the timetable for the implementation of the shareholder approved 100:1 share consolidation to ensure the Company's securities trade on both the ASX and NASDAQ, on the same consolidated basis, from the same date. The company continues to develop risk assessment products and offers cancer predictive testing and assessment tools to help improve health outcomes for individuals worldwide. Shareholders are advised to stay informed about the updated timetable for the share consolidation. It's important to note that forward-looking statements in the announcement are subject to risks and uncertainties, and the Company does not undertake any obligation to publicly update these statements, except as required by law.